Sagimet Biosciences Form 4 Change in insider ownership

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

KPCB PBD Associates, LLC

(Last)

(First)

(Middle)

C/O KLEINER PERKINS CAUFIELD & BYERS

2750 SAND HILL ROAD

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/18/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/18/2023		J⁽¹⁾		38,763	D	⁽¹⁾	0	I	See footnote⁽²⁾
Series A Common Stock	07/18/2023		J⁽¹⁾		38,763	A	⁽¹⁾	38,763	I	See footnote⁽²⁾
Series A Common Stock	07/18/2023		C⁽³⁾		1,860,712	A	⁽³⁾	1,899,475	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			539,006	⁽³⁾	⁽³⁾	Common Stock	6,781	$0	0	I	See footnote⁽²⁾
Series B Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			493,370	⁽³⁾	⁽³⁾	Common Stock	6,208	$0	0	I	See footnote⁽²⁾
Series B-1 Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			8,596,590	⁽³⁾	⁽³⁾	Common Stock	108,163	$0	0	I	See footnote⁽²⁾
Series C Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			8,596,589	⁽³⁾	⁽³⁾	Common Stock	108,163	$0	0	I	See footnote⁽²⁾
Series D Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			6,103,580	⁽³⁾	⁽³⁾	Common Stock	76,796	$0	0	I	See footnote⁽²⁾
Series E Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			103,127,234	⁽³⁾	⁽³⁾	Common Stock	1,297,549	$0	0	I	See footnote⁽²⁾
Series F Preferred Stock	⁽³⁾	07/18/2023		C⁽³⁾			20,430,107	⁽³⁾	⁽³⁾	Common Stock	257,052	$0	0	I	See footnote⁽²⁾

1. Name and Address of Reporting Person^*

KPCB PBD Associates, LLC

(Last)

(First)

(Middle)

C/O KLEINER PERKINS CAUFIELD & BYERS

2750 SAND HILL ROAD

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

KPCB PANDEMIC & BIO DEFENSE FUND LLC

(Last)

(First)

(Middle)

C/O KLEINER PERKINS CAUFIELD & BYERS

2750 SAND HILL ROAD

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

Explanation of Responses:

1. Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was reclassified into one share of Series A Common Stock.

2. Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted into on a 79.4784-to-one basis into Series A Common Stock. The Preferred Stock had no expiration date.

3. Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". KPCB PBD Associates disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

	KPCB PBD Associates, LLC, By: /s/ Susan Biglieri, CFO	07/20/2023
	KPCB Pandemic and Bio Defense Fund, LLC, By: KPCB PBD Associates, LLC, its managing member, By: /s/ Susan Biglieri, CFO	07/20/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Sagimet Biosciences (SGMT) Form 4Change in insider ownership